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To describe the two-year real-world clinical outcomes after transition to psychosis in patients 
at clinical high-risk. 
 
Methods 
Clinical Electronic Health Record (EHR) cohort study including all patients receiving a first 
index primary diagnosis of non-organic ICD-10 psychotic disorder within the early psychosis 
pathway in the SLaM NHS Trust from 2001 to 2017. Outcomes encompassed: cumulative 
probability (by 3-, 6-, 12-, 24-months) of receiving a first (i) treatment with antipsychotic, (ii) 
informal admission and (iii) compulsory admission, (iv) treatment with clozapine and (v) 
numbers of days spent in hospital (by 12- and 24-months) in patients transitioning to 
psychosis from clinical high-risk services (OASIS) compared to other first-episode groups. 
Analyses included logistic and zero-inflated negative binomial regressions. 
 
Results 
1,561 patients were included; those who had initially been managed by OASIS and had 
subsequently transitioned to a first-episode of psychosis (n=130) were more likely to receive 
antipsychotic medication (by 3-, 6-, 24-month, all P<0.023), to be admitted informally (at all 
timepoints, all P<0.004) and on a compulsory basis (at all timepoints, all P<0.013), and to 
have spent more time in hospital (all timepoints, all P<0.007) than first-episode patients who 
were already psychotic when seen by the OASIS service (n=310), or presented to early 
intervention services (n=1,121). The likelihood of receiving clozapine was similar across all 
groups (by 12-/24-month, all P<0.101).  
 
Conclusions 
Transition to psychosis from a clinical high-risk state is associated with severe real-world 
clinical outcomes. Prevention of transition to psychosis should remain a core target of future 
research.  
 
Study protocol registration: researchregistry5039 (www.researchregistry.com). 
INTRODUCTION 
Preventive approaches in young, help-seeking individuals presenting with attenuated 
psychotic symptoms1 and functional impairments2 to specialised clinical services, and 
meeting a Clinical High-Risk state for Psychosis (CHR-P)3, have the potential to maximise 
the benefits of early interventions for the most severe psychiatric disorder4,5. Two decades 
since being first conceived6,7, the essence of the CHR-P paradigm remains its capacity to 
prospectively identify individuals at increased risk of “transition” to psychosis from an at-risk 
stage8. Accordingly, research has mostly focused on the identification of robust predictors of 
transition to psychosis9 or on effective treatments to prevent a first-episode of psychosis 
(FEP)10 from a CHR-P state.  
However, the concept of transition to psychosis from a CHR-P state has always been under 
fire. Transition to psychosis is dichotomously defined (i.e. transition to psychosis vs non-
transition to psychosis) in terms of “above-threshold” (i.e. more than a certain cutoff of 
severity and/or frequency on the CHR-P psychometric instruments11) positive psychotic 
phenomena, such as delusions and hallucinations8. Such a threshold is psychometrically 
arbitrary because it was introduced to guide the clinical commencement of antipsychotic 
treatments in CHR-P individuals12. Furthermore, the psychosis threshold in the CHR-P 
assessment tools is different from that employed in standard ICD and DSM psychiatric 
classifications13. For example, individuals with Brief and Limited Intermittent Psychotic 
Symptoms are considered at-risk and not psychotic under the CHR-P approach but already 
psychotic under the ICD or DSM approaches14,15. A further bias is that transition to psychosis 
(as an outcome) is measured on the same dimensional scale that defines the CHR-P state 
(as a predictor), producing “artificial diagnostic shifts”16. Furthermore, the use of a crude 
dichotomous diagnostic outcome in individuals who frequently have several comorbid non-
psychotic mental disorders17 may be questionable13, because it does not reflect the 
underlying clinical complexity. A collateral issue is that the risk of transition to psychosis in 
CHR-P individuals has declined from 31.5% at 3-year (2012 meta-analysis18) to 22% at 3-
year (2016 meta-analysis19), although not globally20. In light of the sampling biases that 
reduce the epidemiological validity of the paradigm 21, low impact of the CHR-P approach for 
detecting patients at risk22,23, and high insight in CHR-P individuals (which is associated with 
good outcomes24), it has been claimed that CHR-P individuals reflect an intrinsically good-
prognostic subgroup which represents a “different illness” compared to more sever psychotic 
disorders such as schizophrenia16. There is thus converging criticism across different 
authors8,12,13,16 that the concept of transition to psychosis from a CHR-P stage may be 
irrelevant in terms of real-world clinical outcomes16. Over the past decade, several authors 
have indicated that it is essential to test whether the transition to psychosis in CHR-P 
individuals has any validity in terms of outcome12 but surprisingly no large-scale studies 
have been published to date. 
 
This study addresses this gap in knowledge by describing, for the first time, the real-world 
clinical outcomes of CHR-P individuals who have transitioned to psychosis, compared to 
patients who first present at the FEP stage. In line with the evidence above, we 
hypothesised that CHR-P individuals transitioning to psychosis would represent a subgroup 




Retrospective cohort study using Electronic Health Records (EHRs). 
 
Data source 
The Clinical Record Interactive Search -CRIS- tool (CRIS25) provides contemporaneous 
EHR and ‘real-world’ data on routine mental healthcare26 from all patients managed by the 
South London and Maudsley (SLaM) NHS Foundation Trust. SLaM is a UK National Health 
Service (NHS) mental health trust that provides secondary mental health care to a 
population of 1.36 million individuals in South London (Lambeth, Southwark, Lewisham and 
Croydon boroughs). In SLaM there is one of the highest rates of psychosis in the world27. In 
terms of the quality of SLaM/CRIS records, SLaM was an early pioneer of electronic health 
records and the trust is effectively digitised and paper-free25. SLaM has a near-monopoly in 
terms of secondary mental healthcare provision to its local catchment area, and it is a legal 
requirement for SLaM healthcare professionals to keep these records up to date25. Whereas 
many national registers capture only those patients who have been hospitalised, the 
SLaM/CRIS register contains the full clinical records of all patients, which are continually 




All individuals accessing SLaM from January 2001 to July 2017 and receiving a first primary 
diagnosis of non-organic ICD-10 psychotic disorder (see eMethod 1) in the local early 
psychosis pathway. SLaM covers a catchment area in South-London encompassing the 
boroughs of Lambeth (total population, 334,724) and Southwark (total population, 322,302), 
Lewisham (total population, 310,324) and Croydon (total population, 391,296) 28. Incidence 
of psychosis in Lambeth, Southwark, Lewisham and Croydon is estimated at 71.9, 69.6, 
71.3, 58.3 cases per 100,000 person-years respectively, which is higher than England 
national average of 34.9 cases28. In SLaM there is one of the highest incidence of psychosis 
of the world29. 
 
The local early psychosis pathway included: Early Intervention Services (EI) for assessment 
and treatment of individuals with FEP, and early detection services such as the Outreach 
And Support In South-London (OASIS30) for individuals with CHR-P. However, about one 
third of referrals to OASIS are presenting with FEP31 and are immediately referred to EI for 
treatment (see below). Individuals who were given a first primary diagnosis of non-organic 
ICD-10 psychotic disorder by either EI or OASIS services were initially included. 
Subsequently, individuals who did not match the age range of the OASIS-T group (below) 
were subsequently excluded. The individuals thus selected were then assigned to three non-
overlapping clinical subgroups that are described below. 
 
Clinical subgroups 
OASIS30 is an early detection service which was set up in 2001, and it is one of the oldest 
CHR-P services in the UK30. OASIS focuses on the identification, prognostic assessment 
and treatment of help-seeking CHR-P individuals aged 14-35 years, serving the same 
catchment area population as other SLaM services (below). OASIS is integrated in the Pan-
London Network for Psychosis-prevention (PNP)28. The OASIS-transitioning (OASIS-T) 
group comprised patients who had initially presented to OASIS with a CHR-P state 
(ascertained using the Comprehensive Assessment of At Risk Mental States, CAARMS32), 
and who had subsequently transitioned to psychosis during a 2-year follow-up period.  
 
OASIS receives referrals from a variety of agencies30, and about one-third of them 
represents undetected cases of FEP from the community (OASIS-First Episode, OASIS-
FEP)31. This group included individuals who had been referred to OASIS but on initial 
CAARMS assessment were found to already be experiencing a FEP (rather than CHR-P). In 
both the OASIS-T and OASIS-FEP groups, the diagnostic threshold for a FEP was assessed 
by OASIS clinicians using the CAARMS.  
 
The Early Intervention-First Episode (EI-FEP) group included patients who received a 
diagnosis of FEP from SLaM EI services, and not from the OASIS as it is the case of the 
OASIS-FEP group. These services (established in 200133,34) closely interact with OASIS and 
are specialised for patients with FEP, comprising an assertive outreach community team in 
each of the four SLaM boroughs, as well as an inpatient unit. These services provided care 
for individuals aged 16-35 until April 2016, after which the upper age limit was extended to 
6535.  
 
Because all OASIS patients upon transition (OASIS-T) or detection (OASIS-FEP) are 
typically referred to EI services, the current cohort has been offered the same standard type 
of care for FEP throughout the course of the study. The type of FEP care is mandated by the 
NICE Clinical Guideline 178 (https://www.nice.org.uk/guidance/cg178)36 which have been 
implemented in 2014 and became a national standard. This included crisis resolution and 
home treatment teams, which became mandatory in England in 2000 under the National 
Health Service (NHS) Plan37 and operate around the clock, offering rapid access and 
intensive support in the community to prevent the need of hospitalisation38,39. The first-line 
recommended therapy of EI services following FEP onset is antipsychotic medication 
alongside psychosocial interventions36.  
 
Approval for the study was granted by the Oxfordshire Research Ethics Committee C. 




Baseline descriptive variables included sociodemographic (age, sex, ethnicity, marital status, 
employment status, accommodation status) and clinical characteristics (the diagnostic 
cluster and Health Of the Nation Outcome Scale [HONOS]40, eMethod 1). Additional 
baseline variables that described the OASIS-T patients ahead of their development of 
psychosis onset included the type of CHR-P, classified as APS (APS only or APS plus 
GRD), BLIPS (BLIPS only, BLIPS plus APS or BLIPS plus APS plus GRD) and GRD only, in 
line with previous studies41, the severity of CHR-P symptoms (operationalised as the 
summed scores of the product of global rating scale score (0-6) and frequency (0-6) of the 
four CAARMS42 subscales, in line with previous studies43) at the time of their first contact 
with OASIS, functional status (Social and Occupational Functioning Assessment Scale 
[SOFAS]44) at first presentation with OASIS and the duration of the CHR-P stage (defined by 
the period between the first presentation to OASIS and the date of transition to psychosis). 
 
Follow-up 
In all groups, follow-up started at the time of their index diagnosis of psychosis and ended 
when a primary outcome was recorded, or when the patient dropped out of the EHR (as 
documented by the last entry on CRIS), or when the 2-year follow-up had been completed. 
 
Primary outcomes 
The primary outcomes of the current study were the cumulative probability (from intake to 3, 
6, 12, 24 months) of first receiving (i) treatment with antipsychotic medication, (ii) informal 
admission to a mental health hospital, (iii) compulsory admission to a mental health hospital 
(involving a Mental Health Act -MHA- assessment), (iv) treatment with clozapine, and (v) the 
numbers of days spent in hospital (by 12 and 24 months) in the OASIS-T group, compared 
to other FEP groups. 
 
Statistical analysis 
This clinical register-based cohort study (study protocol registered on 
www.researchregistry.com, researchregistry5039) was conducted according to the 
REporting of studies Conducted using Observational Routinely-collected health Data 
(RECORD) Statement45 (see supplementary checklist). Sociodemographic and clinical 
characteristics of the sample (including missing data), were described with mean and SD for 
continuous variables, absolute and relative frequencies for categorical variables, and 
compared with ANOVA and chi-square tests; post-hoc analyses were conducted to clarify 
between-groups differences. The cumulative probability of receiving a first treatment with 
antipsychotic medication, a first informal admission to a mental health hospital, a first 
compulsory admission to a mental health hospital, and a first treatment with clozapine were 
investigated with complete-case logistic regression (Odds Ratio, OR) analyses at different 
timepoints; the number of cases at risk (not dropped out) was reported. Because the 
numbers of days spent in hospitals were characterised by an excess of zero values and 
overdispersion, they were analysed with complete-case zero-inflated negative binomial 
regression analyses, which are suited for modelling count variables with excessive zeros 
and overdispersed count outcome variables46. Furthermore, sensitivity analyses were 
conducted to test the potential impact of a priori confounders such as the different types of 
index diagnoses of psychosis5. For all analyses, statistical tests were two-sided, and 
significance was defined as a p-value of < 0.05. All analyses were conducted in STATA 14 
(STATA Corp., TX, USA). 
 
RESULTS 
Baseline characteristics of the sample 
As shown in Figure 1, 1,587 individuals received a primary index diagnosis of ICD-10 non-
organic psychotic disorder in SLaM early intervention psychosis pathway services during the 
study period. The age range of OASIS-T patients at the point of transition to psychosis was 
14-38. Therefore, individuals outside this age range (n=26) were excluded from further 
analysis, leaving a final population of 1,561 individuals (the proportion with missing 
diagnostic data was very small). The final cohort included n=130 individuals in the OASIS-T 
group, n=310 in the OASIS-FEP group and n=1,121 in the EI-FEP. There were no group 
difference in sex, ethnicity, marital status but significant group differences (Table 1) in age 
(OASIS-FEP patients were relatively younger than the EI-FEP: F=26.796, P<0.001 and 
OASIS-T: F=26.253, P=0.003 but there were no differences between the OASIS-T and EI-
FEP groups: F=1.68, P=0.195), employment status (there were more students and fewer 
unemployed patients in the OASIS-T compared to the EI-FEP group: F=30.785, P<0.001 but 
no differences between the OASIS-T and the OASIS-FEP group: F=4.726, P=0.094), 
accommodation status (there were more homeless/patients receiving a supported 
accommodation in the OASIS-T compared to the other groups) HONOS scores (higher in 
the OASIS-FEP than in the EI-FEP group: F=14.13, P<0.001; no differences between the 
OASIS-T and the other groups: all P>0.05) and type of index psychotic diagnoses 
(schizophrenia spectrum psychoses were more frequent in the EI-FEP group, affective 
spectrum psychoses in the OASIS-T group, psychoactive substance use psychoses in the 
OASIS-FEP group, Acute and Transient Psychotic Disorders in the EI-FEP group: all 
F>16.623, all P<0.002). For 6 patients the CHR-P subgroup was not known; among the 
others there were 87 (70.16%) APS, 36 (29.03%) BLIPS and 1 GRD (0.81%). At the time of 
presentation to OASIS, the average total CAARMS score was 42.71 (SD=19.22), the 
average SOFAS was 53.97 (SD 13.19), and the average duration of the CHR-P stage was 
of 552.27 days (SD 762.55). 
 
Clinical outcomes in CHR-P patients 
 
Cumulative probability of receiving a first treatment with antipsychotic medication 
The OASIS-T group was more likely to have received antipsychotic medication than the 
other three groups by 3-, 6- and 24-month; by 12-month it was more likely to have received 
antipsychotics than the EI-FEP group, but not the OASIS-FEP group, (Figure 1 and Table 
2a; the frequency of antipsychotic treatment by 24-month was: 96.33% OASIS-T, 88.43% 
OASIS-FEP, 80.29% EI-FEP). 
 
Cumulative probability of receiving a first informal admission to a mental health hospital 
The OASIS-T group was more likely to have had an informal admission to a mental health 
hospital than the other two groups at all timepoints (Figure 1, Table 2a and 2b; the frequency 
of informal admission by 24-month was: 47.56% OASIS-T, 29.27% OASIS-FEP, 18.20% EI-
FEP). 
 
Cumulative probability of receiving a first compulsory admission to a mental health hospital 
The OASIS-T group was more likely to have had a compulsory admission to a mental health 
hospital than the other two groups at all timepoints (Figure 1, Table 2a and 2b; the frequency 
of compulsory admission by 24-month was: 46.51% OASIS-T, 29.35% OASIS-FEP, 20.96% 
EI-FEP). 
 
Cumulative probability of receiving a first treatment with clozapine 
There were no patients receiving clozapine by 3- and 6-month. However, by 12- and 24-
month, there was no significant difference in the likelihood of having been treated with 
clozapine between the OASIS-T patients and the other two groups (Table 2a and 2b; by 24 
months clozapine frequency was 6.94% in OASIS-T, 3.16% in OASIS-FEP, 3.21% in EI-
FEP). Since these results are based on small counts, they are not plotted in Figure 1. 
 
Numbers of days spent in hospital 
The OASIS-T patients spent more days in mental health hospitals than any other group by 
both 12- (any P<0.001) and 24-month (any P<0.007; by 24-month: OASIS-T 63.21 days, 
SD=128.44; OASIS-FEP 29.14 days, SD 72.33; EI-FEP 1.86 days, SD 17.95). 
 
Sensitivity analyses 
The type of ICD10 index psychotic diagnoses did not impact any outcome, with the 
exception of the days spent in hospitals: the OASIS-T group spent more days in mental 
health hospitals than the EI-FEP and FEP -but not OASIS-FEP- groups by 12-month 
(eResults 2a and 2b). 
 
DISCUSSION  
To our knowledge, this is the first large-scale cohort study to examine clinical outcomes in 
CHR-P individuals transitioning to psychosis compared to other patient groups receiving an 
index diagnosis of a FEP. This group had more severe clinical outcomes than FEP patients 
whose first presentation to services was when they were frankly psychotic. 
 
Because only a minority of CHR-P individuals develop psychosis (22% by 3-year19), it is 
challenging to ascertain large samples that have transitioned to psychosis. A strength of the 
present study is that the largest cohort of CHR-P subjects which was followed clinically for 
two years after they had become psychotic (n=130). Further strengths were that the OASIS-
T group was compared with age-matched FEP groups, and the psychosis threshold and 
index diagnoses were measured using an anchor (i.e. the ICD) independent to that used to 
define the CHR-P state (i.e the CAARMS). Clinical follow-up of large numbers of patients 
was facilitated by the use of well-validated software for searching EHRs26,47. 
 
Contrary to our hypothesis, the OASIS-T group had significantly more severe clinical 
outcomes than the other two FEP groups on most measures, at most timepoints: they were 
more likely to have received antipsychotic treatment (by 3-, 6-, 24-month), to have been 
admitted informally (at all timepoints) and on a compulsory basis (at all timepoints) to mental 
health hospital, and spent more days in hospital (at all timepoints). In the context of a 
naturalistic and non-randomised study, these results should be interpreted with caution. 
Associations (i.e. ORs) are not causations, and potential clinical and sociodemographic 
confounders must be considered. 
The main between-group differences related to the type of psychotic disorders. Since the 
type of psychotic disorder (e.g. schizophrenia spectrum vs other types of psychotic 
disorders), is associated with clinical outcomes5, we entered this covariate in the analyses. 
The core results remained unchanged. The OASIS-T group included a similar proportion of 
black and female people and had a comparable average age and HONOS score than the EI-
FEP group. Despite the higher proportion of students, the OASIS-T also included higher 
proportions of socially deprived (e.g. homeless) people, and the average HONOS score (an 
index of overall clinical severity) was 12.84, compared to 8.05 for patients discharged from 
inpatient mental health units48: social deprivation and higher baseline clinical severity have 
previously been associated with more severe outcomes in patients with psychosis49,50. 
Therefore, these findings contradict the assumptions that because this population is help-
seeking, it is higher functioning, better educated, more affluent and more likely to be white 
than a typical patient with psychosis. Contrary to previous claims16, we found no evidence 
that patients who develop psychosis after first being seen by CHR-P services represent a 
subgroup with relatively good outcomes. 
 
Other potential confounders could be treatments received over follow-up and pathways to 
care. However, we found that they had more severe clinical outcomes at almost all of the 
follow-up timepoints, despite having received clinical care during the CHR-P phase (needs-
based interventions encompassing close-in monitoring, psychosocial support and 
psychoeducation51) and cognitive behavioural therapy (whose specific efficacy is 
uncertain10,52,53) that was not provided to the other FEP patients. Furthermore, on transition 
to psychosis, OASIS-T patients were typically referred to the local EI services; therefore, all 
patients in the current study were offered the standard type of care recommended for FEP, 
which aligns with the NICE clinical guidance 178. It is thus unlikely that systematic 
differences in the local package of care received may have confounded the outcomes 
observed. 
 
Our current findings confirm recent studies which suggest that a history of symptoms 
consistent with a CHR-P state (in this case assessed by retrospectively screening health 
records in FEP patients in the absence of a real CHR-P interview and prospective follow-up 
for transition) is associated with more severe psychotic symptoms and poorer global 
functioning 1 year following a FEP54. The present study extends these findings by 
demonstrating that outcomes are also more severe 2 years after psychosis onset, even in 
patients who received a high level of specialised mental health input that is designed to 
prevent transition to psychosis during the CHR-P phase. This raises the possibility that these 
patients may actually have a more insidious and severe form of psychotic disorder than 
other FEP patients. 
 
Further evidence that CHR-P patients who transition to psychosis do not represent a good 
prognosis subgroup was available from rates of clozapine prescribing after illness onset. By 
both 12- and 24-months OASIS-T patients were just as likely (6.94%) as the other groups 
(e.g. EI-FEP 3.21%) to have received clozapine treatment, which is a proxy marker for 
treatment-resistant psychosis. Although this finding is based on limited statistical power and 
therefore it should be interpreted cautiously, it is in line with a previous small-scale report 
showing that CHR-P patients (n=18) who transitioned to psychosis were more likely to have 
been prescribed more than one antipsychotic medication (90% vs 68%) and to have 
received clozapine (38% vs 2%) than FEP patients detected by EI services55. 
 
Overall, the current study confirms that developing a FEP following a CHR-P stage has a 
prognostic value for predicting clinical outcomes54. The findings of the current study 
considered together indicate that transition to psychosis after a CHR-P stage is not a “trivial” 
event16 because it is associated with more severe real-world outcomes compared to other 
patients with FEP. While future research is certainly needed to better address the 
heterogeneous clinical outcomes of this population, such as remission or persistence of 
disability or functional impairment56, this should not happen at the expense of dismissing 
transition to psychosis. The main clinical implication is that drug development and discovery 
should still consider prevention of psychosis onset from a CHR-P stage as an important 
clinical outcome. On a parallel line, our findings can also inform clinical guidelines to clearly 
recommend close monitoring and intensive care for CHR-P individuals who transition to 
psychosis.  
 
One limitation of this study is that it did not employ structured psychometric interviews to 
ascertain the index psychotic diagnoses and their diagnostic stability57. Therefore, while the 
current EHR findings have high ecological validity (i.e. they represent real-world clinical 
practice), they have not been subjected to formal validation with research-based criteria. 
However, while this issue is relevant for patients who presented to generic mental health 
services, in those that were assessed by OASIS or EI teams the diagnosis of FEP was 
formulated by experienced clinicians with specialist expertise in the assessment and 
diagnosis of emerging psychosis. Furthermore, the aim of the present study was to assess 
real-world clinical outcomes rather than psychometric outcomes in FEP; the use of 
structured diagnostic interviews in research settings can itself lead to the selection of white, 
more highly educated and “squeaky-clean”58 patient subsamples59, further exaggerating 
sampling biases that are already affecting this field21. There is also meta-analytical evidence 
indicating that for psychotic categories, administrative data recorded in clinical registers are 
generally predictive of a true diagnosis60 (see also eLimitation). Another limitation is that 
patients moving outside the SLaM catchment area may have not been followed up. 
However, with the exclusion of clozapine treatment, for any other outcome the proportion of 
missing data at follow up was less than 4%. A further limitation is that, because of HONOS 
data missingness at follow-up, we were unable to use HONOS changes from baseline to 
follow-up as a covariate. Importantly, the current study simply described outcomes without 
addressing the effectiveness of early detection (CHR-P) clinics compared to other mental 
health services. Testing the effectiveness of CHR-P clinics would require randomised 
designs, which are ethically and logistically difficult to implement. Because of these 
limitations, it is not possible to interpret the results of the current study to conclude that 
CHR-P services are ineffective in improving outcomes of these patients. It is still possible 
that individuals who access CHR-P clinics and who would later on develop psychosis would 
have a chance of having prevented such transition, while those who do convert may be the 
ones with an inherently insidious outcome and poor prognosis.  
 
CONCLUSION 
Transition to psychosis from a CHR-P state is associated with more severe real-world 
clinical outcomes than in other FEP patients. There was no evidence to support the notion 
that CHR-P individuals who transition to psychosis represent an atypical good prognosis 
subgroup. While future replication studies are needed, these findings indicate that 
prevention of psychosis in CHR-P individuals should remain a core target of empirical 
prognostic and interventional research. 
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Figure 1. Flow chart of the study population. OASIS-T: FEP patients detected by OASIS 
following a clinical high-risk state; OASIS-FEP: FEP patients detected by OASIS at 























Patients receiving a first ICD-10 index primary 
diagnosis of non-organic psychotic mental disorder 
within SLaM early psychosis pathway in the period 
2001-2017 (n=1,587).  
Eligible early psychosis pathway population                                          
(n=1,561) 
Excluded due to age differences with 
OASIS population (n=26)  
Missing ICD-10 diagnostic code                              
(n= 10, 0.64%) 




Table 1. Sociodemographic and clinical characteristics of the sample. OASIS-T: FEP patients detected by OASIS following a clinical high-risk 
state; OASIS-FEP: FEP patients detected by OASIS at presentation; EI-FEP: FEP patients detected by Early Intervention for psychosis 
services. 
  OASIS-T OASIS-FEP EI-FEP Test 
Continuous variables   N mean SD N mean SD N mean SD SD F P 




4.896 1121 25.615 5.150 6.428 23.02 <0.001 
HONOS tot  80 12.84 6.221 210 13.65
8 
5.539 1040 10.964 10.076 9.837 8.20 0.001 
Categorical variables Levels N count % N count % N count % % X2 P 
Sex  130   310    1121       
 Male  78 60.00   205 66.13  738 65.83 64.11 1.842 0.398 
 Female  52 40.00   105 33.87  383 34.17 35.89   
Self-assigned ethnicity  130   306    1075       
 Any white  44 33.85   98 32.03  336 31.26 39.22 3.949 0.683 
 Any black  65 50.00   152 49.67  526 48.93 41.97   
 Any Asian  10 7.69   15 4.90  67 6.23 7.75   
 Any other (a)  11 8.46   41 13.40  146 13.58 11.06   
Marital status (b)  121   295    1047     7.640 0.106 
 In a relationship  14 11.57   37 12.54  85 8.12 11.37   
 Separated or divorced  5 4.13   7 2.37  42 4.01 4.91   
 Single  102 84.30   251 85.08  920 87.87 83.72   
Employment status (b)  123   290    347     41.127 <0.001 
 Employed  27 21.95   68 23.45  44 12.68 8.75   
 Student  38 30.89   61 21.03  46 13.26 9.82   
 Unemployed  58 47.15   161 55.52  257 74.06 81.43   
Accommodation status (b) 118   288    647     12.269 0.015 
 Owner  3 2.54   2 0.69  5 0.77 1.33   
 
Homeless or supported 
accommodation 
 30 25.42   42 14.58  139 21.48 17.37   
 Other  85 72.03   244 84.72  503 77.74 81.3   
ICD-10 index diagnosis 126   304    1121     170.95 <0.001 
 
Schizophrenia spectrum 
psychoses  26 20.63   53 17.43  257 22.93 49.33   
 
Affective spectrum 
psychoses  29 23.02   34 11.18  71 6.33 10.67   
 
Psychoactive substance 
use psychoses  13 10.32   47 15.46  22 1.96 5.41   
 ATPD  9 7.14   51 16.78  353 31.49 17.03   
 Other psychoses  49 38.89   119 39.14  418 37.29 17.55   
(a) Including mixed ethnicities; (b) self-assigned.
Figure 2. Real-world clinical outcomes in patients with a first-episode of psychotic (FEP) disorder. 
OASIS-T: FEP patients detected by OASIS following a clinical high-risk state; OASIS-FEP: FEP 























































































Table 2a. Group differences in real-world clinical outcomes in patients with an index diagnosis of non-organic first-episode of psychosis. 
  3 months 6 months 
  N OR SE z P 95%CIs N OR SE z P 95%CIs 
Antipsychotic 1533    0.003   1525    0.001    
 OASIS-T  1       1       
 OASIS FEP  0.475 0.129 -2.74 0.006 0.279 0.809  0.436 0.138 -2.62 0.009 0.234 0.810 
 EI-FEP  0.456 0.114 -3.15 0.002 0.280 0.743  0.381 0.112 -3.30 0.001 0.214 0.676 
Informal admission 1526    <0.001   1505    <0.001    
 OASIS-T  1       1       
 OASIS FEP  0.298 0.090 -4.02 <0.001 0.165 0.537  0.450 0.124 -2.90 0.004 0.263 0.771 
 EI-FEP  0.141 0.037 -7.48 <0.001 0.084 0.235  0.185 0.046 -6.85 <0.001 0.114 0.300 
Compulsory admission 1525    <0.001   1502    <0.001    
 OASIS-T  1       1       
 OASIS FEP  0.340 0.097 -3.78 <0.001 0.195 0.595  0.396 0.108 -3.40 0.001 0.232 0.675 
 EI-FEP  0.189 0.046 -6.79 <0.001 0.117 0.305  0.215 0.051 -6.49 <0.001 0.135 0.342 
Clozapine 1121    (a)   1121    (a)    
 OASIS-T  1(a)       1(a)       
 OASIS FEP  1(a)       1(a)       
 EI-FEP  1       1       
         N Coeff SE z P 95%CIs 
Days spent in hospital        1477    <0.001    
 OASIS-T         0       
 OASIS FEP         -0.833 0.221 -3.77 <0.001 -1.267 -0.400 
 EI-FEP         -4.180 0.358 -11.67 <0.001 -4.882 -3.478 
a) There were no cases in this group; OASIS-T: first-episode of psychosis patients detected by OASIS following a clinical high-risk state; OASIS-FEP: first-episode of 
psychosis patients detected by OASIS at presentation; EI-FEP: first-episode of psychosis patients detected by early intervention for psychosis services. 
 
Table 2b. Group differences in real-world clinical outcomes in patients with an index diagnosis of non-organic first-episode of psychosis 
  12 months 24 months 
  N OR SE z P 95%CIs N OR SE z P 95%CIs 
Antipsychotic 1512    <0.001   1498    <0.001    
 OASIS-T  1       1       
 OASIS FEP  0.516 0.191 -1.79 0.074 0.250 1.066  0.291 0.158 -2.27 0.023 0.100 0.846 
 EI-FEP  0.342 0.116 -3.17 0.002 0.176 0.664  0.155 0.080 -3.62 <0.001 0.057 0.426 
Informal admission 1465    <0.001   1408    <0.001    
 OASIS-T  1       1       
 OASIS FEP  0.437 0.114 -3.17 0.002 0.262 0.729  0.456 0.123 -2.92 0.004 0.269 0.773 
 EI-FEP  0.219 0.050 -6.69 <0.001 0.140 0.342  0.245 0.057 -6.00 <0.001 0.155 0.388 
Compulsory admission 1465    <0.001   1408    <0.001    
 OASIS-T  1       1       
 OASIS FEP  0.521 0.137 -2.48 0.013 0.311 0.873  0.478 0.127 -2.78 0.005 0.284 0.805 
 EI-FEP  0.319 0.072 -5.03 <0.001 0.204 0.497  0.305 0.070 -5.20 <0.001 0.195 0.477 
Clozapine 1455    0.213   1383    0.318    
 OASIS-T  1       1       
 OASIS FEP  0.198 0.244 -1.31 0.189 0.018 2.213  0.437 0.272 -1.33 0.183 0.129 1.479 
 EI-FEP  0.810 0.609 -0.28 0.779 0.186 3.532  0.445 0.219 -1.64 0.101 0.169 1.170 
         N Coeff SE z P 95%CIs 
Days spent in hospital        1403    <0.001    
 OASIS-T         0       
 OASIS FEP         -0.774 0.287 -2.7 0.007 -1.337 -0.212 
 EI-FEP         -3.525 0.356 -9.89 <0.001 -4.224 -2.827 
OASIS-T: first-episode of psychosis patients detected by OASIS following a clinical high-risk state; OASIS-FEP: first-episode of psychosis patients detected by OASIS 
at presentation; EI-FEP: first-episode of psychosis patients detected by early intervention for psychosis services. 
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